|
Do anemia treatments improve quality of life and physical function in patients with myelodysplastic syndromes (MDS)? A systematic review |
Jul 2023 |
Blood Reviews |
Myelodysplastic Syndromes (MDS) |
|
Considerations for Drug Development in Myelodysplastic Syndromes |
Jul 2023 |
Clinical Cancer Research |
Myelodysplastic Syndromes (MDS) |
|
Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes |
Jul 2023 |
European Journal of Haematology |
Myelodysplastic Syndromes (MDS) |
|
Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress |
Jul 2023 |
Expert Review of Anticancer Therapies |
Myelodysplastic Syndromes (MDS) |
|
Novel targeted C3 inhibitor pegcetacoplan for paroxysmal nocturnal hemoglobinuria |
Jul 2023 |
Clinical and Experimental Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes |
Jul 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study |
Jul 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Are we ready to ring in a new upfront therapy in lower-risk myelodysplastic syndromes? |
Jul 2023 |
Lancet |
Myelodysplastic Syndromes (MDS) |
|
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial |
Jul 2023 |
Lancet |
Myelodysplastic Syndromes (MDS) |
|
Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care |
Jul 2023 |
Transplantation and Cellular Therapy |
Myelodysplastic Syndromes (MDS) |
